Kirby Lester completes sale of pill-counting machines to supplier in Iraq
LAKE FOREST , Ill. Kirby Lester announced Thursday that it had sold several of its KL 15df pill-counting machines to Najmat Burgan, a medical and hospital goods supplier based in Kuwait City.
The company said the recent sale was part of its growing international presence. In the past three months, it has sold its devices to clients in Saudi Arabia, Botswana, Greece, Honduras and others, bringing its total number of customers to more than 30,000.
“When you consider all of the different medications, dispensing methods and manufacturing practices across the globe, only Kirby Lester can address the needs of all customers as well as deliver absolute counting accuracy,” Kirby Lester vice president for business development Christopher Thomsen said in a statement. “No other pharmacy technology has such broad appeal, bridges all of these differences and provides a universal solution.”
Amgen, Takeda cancer drug trials stopped after deaths
NEW YORK Several deaths have brought phase 3 clinical trials of a cancer drug by Amgen and Takeda Pharmaceutical to a halt.
The two companies are investigating the drug, motesanib, as an initial treatment for small-cell lung cancer, to be used in conjunction with chemotherapy.
A committee monitoring the 600-patient study found more had died early using the drug than those receiving placebo.
“While we are disappointed in the outcome, it is consistent with data seen with some other anti-VEGF therapies and appears to constitute a class effect of these types of agents,” Amgen executive vice president for research and development Roger Perlmutter said in a statement.
Elan appoints Paya as president
SOUTH SAN FRANCISCO, Calif. Elan Corp. has appointed Carlos Paya as president, the company announced Thursday.
Paya will work from Elan?s South San Francisco, Calif., campus, focusing on leading the company’s scientific, clinical and medical initiatives.
“As an immunologist, a former vice dean of clinical investigation at the Mayo Clinic and as a successful industry executive, Dr. Paya has a unique set of attributes and experiences that perfectly match the opportunities and challenges facing Elan,” said Elan chairman of the board Kyran McLaughlin in a statement.
Paya previously worked at Eli Lilly & Co. as vice president of Lilly Research Labs and global leader of the Diabetes and Endocrine Platform. He had served as an executive at Lilly since 2001. He also worked for six years at the Mayo Clinic as professor of medicine, immunology and pathology, in addition to his position as vice dean.